Agile Therapeutics, Inc.
Agile Therapeutics develops and commercializes prescription contraceptives for US women. Its flagship product is Twirla, a weekly hormonal patch. The company also has a pipeline of Twirla line extensions and other products, including AG200-15 ER, SmP, ER SmP, and P-Patch.
Overview
Strengths
- The company has low debt. Net Debt to EBITDA Ratio is 0.02 and it is lower than the sector mean.
- The company has high returns. ROIC (67.70%) is higher than the sector mean (14.71%).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 67.7% |
| Net Debt/EBITDA | 0.0 |